Novartis started 2022 on a subtle note, with the lynchpin oncology franchise again failing to revive. However, all the other major franchises like immunology and cardiovascular performed well, and covered up for weaknesses/declines in other areas. Importantly, the profitability improvement continued, despite a tough external environment due to the pandemic and geopolitical crisis, which lends further support to our investment case. Hence, our positive recommendation on the Swiss giant is reitera ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A subtle start to the year
Novartis started 2022 on a subtle note, with the lynchpin oncology franchise again failing to revive. However, all the other major franchises like immunology and cardiovascular performed well, and covered up for weaknesses/declines in other areas. Importantly, the profitability improvement continued, despite a tough external environment due to the pandemic and geopolitical crisis, which lends further support to our investment case. Hence, our positive recommendation on the Swiss giant is reitera ....